

Protein'eXpert Changes Its Name to PX'Therapeutics

GRENOBLE – September 29, 2008 – Protein'eXpert SA today announced that it has changed its name to PX'Therapeutics. The new name builds on an already strong European position as a Contract Research and Manufacturing Organization specialised in the development of recombinant biotherapeutics.

“For more than seven years, Protein'eXpert brand name has been associated to our recombinant protein expertise and we are now recognized as a dedicated and reliable partner who can support protein-based projects from the discovery steps up to small scale cGMP manufacturing. With the set up of new services addressing the development of murine and humanized monoclonal antibodies in 2007 (PX'Monoclonals), we have reinforced our technology platform in order to meet the increasing and diversified needs of the biotech and pharma companies” explained Dr Tristan Rousselle CEO. “Our new corporate identity better reflects our expanded mission – to provide our clients access to a high technical expertise, a flexible and efficient platform and a comprehensive approach to their therapeutic projects development. Moreover, one of our main objectives will remain to ensure seamless transfer from early stage R&D through to pre-clinical and clinical production steps.”

About PX'Therapeutics

Located in Grenoble and Lyon (France), PX'Therapeutics provides integrated biotherapeutics and recombinant vaccines development and manufacturing contract services. Organized around three integrated service platforms (recombinant protein R&D, monoclonal antibody development, cGMP manufacturing), PX'Therapeutics offers custom programmes which may include murine antibody generation, humanization strategy, protein engineering, process development and small scale cGMP manufacturing services (PX'Pharma).

PX'Therapeutics has been extensively involved into the discovery, development and manufacturing of drug targets and therapeutic proteins with over 500 projects performed. The company has thus gained substantial experience in the production of challenging proteins and developed trusted relationships with now more than 120 pharmaceutical, biotech and academic partners (European & American)

For more information, visit www.px-therapeutics.com.

NB : PX'Therapeutics, formerly Protein'eXpert owns 100% of its sister companies : PX'Monoclonals and PX'Pharma.

Contact

PX'Therapeutics SA

Christelle Dagoneau

Business Development Director

+33 4 38 02 36 50

ChristelleDagoneau@px-therapeutics.com